Advanced Enzyme Technologies Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 1 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹3.7K Cr

The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.

From Advanced Enzyme Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹300

Market Cap

₹3.7K Cr

P/E Ratio

24.0

How does Advanced Enzyme Technologies Ltd rank in Pharmaceuticals & Biotechnology?

Compare Advanced Enzyme Technologies Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22).
→Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22).
→There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24).
→Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19).
→The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17).
→U.S. sales volumes are expected to pick up within the current financial year, aided by improved tariff conditions and increased inquiries (Pages 19, 21).
→R&D and new product launches will support sustained growth (Pages 17, 19).

📈 Profitability & Margins

→The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
→Growth will be uneven ("roller coaster"), with some years faster and some slower.
→EBITDA margins may face tariff impacts, but current outlook suggests a worst-case 1% impact (vs. earlier 2%), with efforts to pass costs to customers to mitigate margin pressure.
→Profit before tax and profit after tax have shown increases in recent quarters, reflecting improving financials.
→Expansion of product pipelines, including enzymes, probiotics, biocatalysis, and biopharma areas, is expected to drive future top-line growth.
→New R&D centers and innovations are expected to support growth in new applications and market areas, especially healthcare and biochemical processing.
→U.S. market performance is critical and improving, aided by lower tariffs and strategic customer management, which should enhance earnings going forward.

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→No major CapEx planned for the current fiscal year except for R&D-related investments.
→Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year.
→Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation.
→Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion.
→Continued efforts to invest in R&D and new product pipelines to support growth and market expansion.
→Strategic investments linked to evolving market opportunities such as healthcare, biochemical processing, and industrial enzymes.

💰 Fundraising & Capital Structure

→There is no mention of any current or planned fundraising through debt or equity in the discussion.
→On CapEx, the company plans for potential greenfield or brownfield expansion around FY28-29 with estimated costs of about INR 50 crore.
→CapEx for the current year is limited to R&D Center-related expenses only.
→The company focuses on internal growth, R&D investments, and capacity utilization without indicating external fundraising.
→Board considerations such as buybacks are probabilistic and not confirmed, with no concrete plans announced.

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year.
→The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes.
→There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders.
→No explicit details on the exact size or value of the current order book or pending orders were provided in the call.
→Management emphasizes a pipeline-driven approach rather than reliance on single-product orders, aiming for steady revenue generation as products mature.
→The outlook includes increased inquiries and interest reflecting a healthier order flow expected in the near to medium term.

Key Metrics

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Advanced Enzyme Technologies Ltd

See full Pharmaceuticals & Biotechnology sector rankings

What Advanced Enzyme Technologies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

ONESOURCE (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
MANKIND (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
GLAND (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
SHILPAMED (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q3 FY26 results?

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

No major CapEx planned for the current fiscal year except for R&D-related investments.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.